<DOC>
	<DOCNO>NCT01898065</DOCNO>
	<brief_summary>With functional imaging development , become possible increase radiation dose radioresistant area ( locate inside tumor volume ) use radiotherapy dose-painting . This strategy particularly suitable prostate cancer tumor hypoxia play major role resistance tumor radiation . In order develop intratumoral hypoxia target radiotherapy dose-painting area , characterize change hypoxia treatment radiotherapy . - If hypoxia change radiotherapy , radiotherapy dose-painting strategy `` integrated '' boost perform . - If hypoxia varied ( increase incomplete regression ) , `` final '' boost strategy radiotherapy dose-painting ( IMRT , stereotactic brachytherapy high dose rate ) first fractionate IMRT could consider . This study show PET image fluoromisonidazole ( 18F-MISO ) available tool physician assess tumor hypoxia .</brief_summary>
	<brief_title>Evaluation Hypoxia PET With F-Miso Radiation Therapy Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Anoxia</mesh_term>
	<mesh_term>Misonidazole</mesh_term>
	<criteria>histologically proven prostate adenocarcinoma Absence metastasis ( lymph node bone ) One tumor nodule see MRI PET Choline . Intermediate Risk : Gleason 7 PSA ( prostate specific antigen ) &lt; 20 ng / ml , T &lt; T2c Gleason 6 PSA 1020 ng / ml , T &lt; T2c No concomitant hormonal treatment . ( NB : introduction hormone therapy radiotherapy second 18FMISO criterion study exit ) Indication radiotherapy total dose &gt; 70 Gy 2 Gy/day fraction Signed Informed consent Social Insurance Age &lt; 18 year old Patient protect law</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Hypoxia</keyword>
	<keyword>radiotherapy</keyword>
	<keyword>PET 18-F-MISO</keyword>
	<keyword>MRI</keyword>
</DOC>